Friday, March 08, 2024 9:06:58 AM
March 06 2024
The presentation will also describe key activities completed in support of TransCode’s planned Phase 1/2 trial for which it plans to file an IND in March 2024.
TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that its Chief Scientific Officer, Zdravka Medarova, Ph.D., will present at this year’s RNA Leaders Europe Congress scheduled to take place March 12-14 in Basel, Switzerland. The conference is focused on the development of mRNA, RNAi, ASOs, oligonucleotides, vaccines, microRNAs, genome editing, wider nucleic acids and RNA targets. It is expected that delegates from leading companies in these areas will be in attendance.
Details of the Presentation
Stream: Short RNA Based Therapeutics
Title: A First-in-Class Therapy Against Metastatic Cancer: From Pre-Clinical Testing to Early Clinical Trials
Date and Time: March 14th 2:10 p.m. local time
Dr. Medarova’s presentation will describe work completed in support of the TransCode’s ongoing Phase 0 microdose clinical study with its lead therapeutic candidate, TTX-MC138. TTX-MC138 is designed to be delivered to metastatic tumor cells where it is intended to inhibit miR-10b, generally regarded as a master regulator of metastatic disease. In preclinical studies, TTX-MC138 elicited complete responses and life-long disease remission in animal models of adenocarcinoma.
Nonclinical studies to be presented include dosimetry, pharmacokinetics (PK), tissue distribution, and metabolite analysis. In addition, preliminary clinical results including pharmacokinetics and accumulation of the drug candidate in clinical metastases, as well as drug candidate stability, will be discussed. The presentation will also describe key activities completed in support of TransCode’s planned Phase 1/2 trial for which it plans to file an IND in March 2024.
“We are honored to join key stakeholders in the field of RNA to exchange ideas, share compelling data, and ultimately help further this potentially important technology,“ said Medarova. Dr. Medarova continued, “We believe that TTX-MC138 has the potential to help cancer patients as a first-in-class RNA-based treatment for metastatic disease. We are eager to share our progress with the broader scientific community.”
For more information, please visit:
www.transcodetherapeutics.com and https://informaconnect.com/rna-leaders-europe/
About TransCode
TransCode is a clinical-stage oncology company focused on treating metastatic disease. The company is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company’s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.
Recent RNAZ News
- TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors • GlobeNewswire Inc. • 04/15/2024 01:00:00 PM
- TransCode Therapeutics Reports 2023 Results; Provides Business Update • GlobeNewswire Inc. • 04/03/2024 01:10:00 PM
- TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer • GlobeNewswire Inc. • 03/28/2024 12:30:00 PM
- TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment • GlobeNewswire Inc. • 03/11/2024 01:00:00 PM
- TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress • GlobeNewswire Inc. • 03/06/2024 09:15:00 PM
- TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist Immunotherapeutic • GlobeNewswire Inc. • 02/20/2024 01:00:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/15/2024 09:00:30 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 01:12:31 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/31/2024 09:33:08 PM
- Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders’ Equity Requirement and Continued Listing on The Nasdaq Stock Market • GlobeNewswire Inc. • 01/31/2024 09:05:00 PM
- TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer • GlobeNewswire Inc. • 01/29/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 09:45:50 PM
- TransCode Therapeutics Announces Closing of $7.25 Million Public Offering • GlobeNewswire Inc. • 01/22/2024 09:45:00 PM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 01/20/2024 02:57:15 AM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 01/19/2024 05:15:08 AM
- TransCode Therapeutics Announces Pricing of $7.25 Million Public Offering • GlobeNewswire Inc. • 01/18/2024 06:27:45 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 01/18/2024 03:39:59 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 01/17/2024 12:06:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/16/2024 09:01:22 PM
- TransCode Therapeutics Reports Further Restructuring to Reduce Expenses and Increased Focus on Planned Phase 1 Clinical Trial, Retirement of CEO • GlobeNewswire Inc. • 01/12/2024 09:05:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 01/11/2024 01:22:19 PM
- TransCode Therapeutics Announces 1-for-40 Reverse Stock Split • GlobeNewswire Inc. • 01/11/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 09:01:49 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 01/04/2024 05:41:41 PM
- TransCode Therapeutics Publishes Open Letter Outlining Company’s Progress and Objectives • GlobeNewswire Inc. • 01/04/2024 01:05:00 PM
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM